In sur­pris­ing set­back, com­bo of Roche’s Tecen­triq and chemo fails to help pa­tients with triple-neg­a­tive breast can­cer

Roche broke ground last year when they se­cured the first FDA ap­proval for a check­point ther­a­py in triple-neg­a­tive breast can­cer, a no­to­ri­ous­ly dif­fi­cult-to-treat in­di­ca­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER